Cardiff Oncology is advancing its oral, highly selective PLK1 inhibitor, onvansertib, across multiple oncology indications with promising Phase 2 trial data in RAS-mutated metastatic colorectal cancer demonstrating improved objective response rates and progression-free survival. Despite scientific progress and a collaborative relationship with Pfizer Ignite enhancing clinical trial execution, Cardiff faces significant operational headwinds highlighted by recent CEO and CFO departures, persistent operating losses exceeding $48 million annually, and increasing R&D expenditures. The company maintains a solid intellectual property portfolio but operates amid patent disputes and regulatory risks that may constrain commercialization timing. Key upcoming milestones include finalizing Phase 3 trial designs and data readouts across pancreatic, lung, breast cancers and leukemia.